Long-Term Tegaserod Treatment for Dysmotility-like Functional Dyspepsia: Results of Two Identical 1-year Cohort Studies

Chey, William D.; Howden, Colin W.; Tack, Jan; Ligozio, Gregory; Earnest, David L.

doi:10.1007/s10620-009-1049-0

Cited by 15 publications

(7 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The OTE was used most recently in the acotiamide trial as a primary endpoint 25 and the tegaserod trial as a secondary endpoint. 26 The seven point Likert scale of OTE in both trials allocated 3 scales for measuring the degree of aggravation from slight to extreme. However, only few patients were reported as being aggravated.…”

Section: Discussionmentioning

confidence: 99%

Randomized, Controlled, Multi-center Trial: Comparing the Safety and Efficacy of DA-9701 and Itopride Hydrochloride in Patients With Functional Dyspepsia

Choi

Rhee

Park

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

Background/AimsTherapies of functional dyspepsia (FD) are limited. DA-9701 is a novel prokinetic agent formulated with Pharbitis semen and Corydalis Tuber. We aimed to assess the efficacy of DA-9701 compared with itopride in FD patients. MethodsPatients with FD randomly received either itopride 50 mg or DA-9701 30 mg t.i.d after a 2-week baseline period. After 4 weeks of treatment, 2 primary efficacy endpoints were analyzed: the change from baseline in composite score of the 8 dyspeptic symptoms and the overall treatment effect. Impact on patients' quality of life was assessed using the Nepean Dyspepsia Index (NDI) questionnaire. ResultsWe randomly assigned 464 patients with 455 having outcome data. The difference of the composite score change of the 8 symptoms between the 2 groups was 0.62, indicating that DA-9701 was not inferior to itopride. The overall treatment effect response rate was not different between the groups. When responder was defined as ≥ 5 of the 7 Likert scale, responder rates were 37% of DA-9701 and 36% of itopride group. Patients receiving DA-9701 experienced similar mean percentage of

show abstract

Section: Discussionmentioning

confidence: 99%

Randomized, Controlled, Multi-center Trial: Comparing the Safety and Efficacy of DA-9701 and Itopride Hydrochloride in Patients With Functional Dyspepsia

Choi

Rhee

Park

et al. 2015

J Neurogastroenterol Motil

View full text Add to dashboard Cite

show abstract

“…Lastly, tegaserod, a partial 5‐HT 4 agonist that was originally on the market for constipation‐predominant IBS and functional constipation, showed to be beneficial in the treatment of FD as well . A large randomised, placebo‐controlled study consisting of two identical trials showed a 4.6% improvement in days with satisfactory symptom relief after 6 weeks of tegaserod treatment (6 mg twice a day) over placebo.…”

Section: Current Treatment Options For Functional Dyspepsiamentioning

confidence: 99%

Review article: treatment options for functional dyspepsia

Masuy

Oudenhove

Tack

2019

Aliment Pharmacol Ther

Self Cite

100

124

View full text Add to dashboard Cite

Background: Functional dyspepsia, consisting of epigastric pain syndrome and postprandial distress syndrome, is a prevalent functional gastrointestinal disorder. To date, only limited treatment options are available and conflicting results in terms of efficacy have been reported. Consequently, nonpharmacological treatment options are increasingly being explored for functional dyspepsia. Aim: To provide an overview of current pharmacological and nonpharmacological treatment options for functional dyspepsia. Methods: A literature search was conducted on Pubmed and other sources to identify relevant studies.Results: Acid suppressive therapy reduced symptoms in 30%-70% of the patients, with higher benefit in epigastric pain syndrome and superior effectiveness for proton pump inhibitors compared to H 2 -antagonists. Prokinetic agents, primarily used to treat postprandial distress syndrome, showed variable efficiency: 59%-81% responder rate for dopamine receptor antagonists, 32%-91% for serotonin-4-receptor agonists and 31%-80% for muscarinic receptor antagonists. H Pylori eradication, recommended in infected patients, was effective in 24%-82%. Refractory symptoms are addressed with neuromodulators. However, their efficacy in functional dyspepsia remains incompletely elucidated, available data showing symptom reduction in 27%-71% of the patients. Regarding herbal agents, peppermint oil reduced symptoms in 66%-91%, rikkunshito in 29%-34% and iberogast in 20%-95%. Lastly, acupuncture, cognitive behavioural therapy and hypnotherapy may help to provide symptom control, but research on their efficacy remains sparse.Conclusions: None of the available therapies is effective in the majority of patients without being associated with major side effects. Developing new treatment options is challenging due to the heterogeneity of functional dyspepsia, the lack of readily identified target mechanisms and the poor association between pathophysiological disturbances and symptoms.

show abstract

“…Despite this limitation, the remaining participants experienced multiple PRO symptom-based improvements. 27 Some of the heterogeneity in these study outcomes is likely attributable to the functional variability of individual serotonin agonists. Cisapride not only stimulates 5-HT 1-4 receptors, but also acts as a potent antagonist of both 5-HT 3 and human ether-a-go-gorelated gene (HERG) K + channels.…”

Section: Discussionmentioning

confidence: 99%

The Efficacy of Mosapride for the Treatment of Functional Dyspepsia

Brenner¹

2010

Clinical Medicine Reviews in Therapeutics

View full text Add to dashboard Cite

Functional Dyspepsia (FD) is a common affliction in western countries effecting approximately 25% of the population. Due to its heterogeneous pathogenesis, effective therapeutics are limited. Mosapride, a serotonin receptor agonist with enterokinetic properties, has been evaluated for treating dyspeptic symptoms in a limited number of clinical trials. Most trials found mosapride to be as effective as other commonly used treatments for FD including histamine receptor blockers (H 2 RAs), and the results of the only randomized double-blind placebo-controlled trial to date found mosapride to be no more effective than placebo. These studies were limited by suboptimal study design and performed prior to sub-classification of FD sub-types as defined by Rome III. Therefore, there is currently inadequate data to comment on the efficacy of mosapride for treating FD. Larger placebo controlled trials differentiating dyspeptic patients by primary symptom associations are necessary.

show abstract

Long-Term Tegaserod Treatment for Dysmotility-like Functional Dyspepsia: Results of Two Identical 1-year Cohort Studies

Cited by 15 publications

References 20 publications

Randomized, Controlled, Multi-center Trial: Comparing the Safety and Efficacy of DA-9701 and Itopride Hydrochloride in Patients With Functional Dyspepsia

Randomized, Controlled, Multi-center Trial: Comparing the Safety and Efficacy of DA-9701 and Itopride Hydrochloride in Patients With Functional Dyspepsia

Review article: treatment options for functional dyspepsia

The Efficacy of Mosapride for the Treatment of Functional Dyspepsia

Contact Info

Product

Resources

About